Stock market technical analysis forecast | Nasdaq trend research for trading investing | 401k
trading penny stock breakout day investing
Skip Navigation Links
    Home
    •   About US
    Market Activity
    World Indices
    Market Watch
    Customer Service
    Learning Center
    Economic Event
    Login


Join Now




Advertise 2 ۩  Daily market forecast

Hot Penny Stock picks for investing - support resistance research

BBI Blockbuster Inc (BBI)
Sector 
RecommendationsBuy
Buy Near0.76
Stop Loss0.70
Posted Date1/18/2010 12:00:00 AM
First resistance0.92
Second resistance1.03
Third resistance1.38
First Support0.60
Second Support0.62
Comments
1/18/2010 12:00:00 AM0) Blockbuster Inc (BBI) is a leading global provider of rental and retail movies and games
1) This penny Stock company (BBI) provides customers with convenient access to media entertainment anywhere, any way they want it - whether in-store, by-mail, through vending kiosks or digitally downloaded directly to their family room or mobile device
2) Blockbuster Inc (BBI) have library of more than 125,000 movies and games
3) Blockbuster Inc (BBI) recently announced that it has eliminated the final $24 million of certain letters of credit it maintained on behalf of its former parent company, Viacom Inc and this stapes naturally increase the liquidity of cash, again Blockbuster Inc (BBI) raised $675 million on our bond offering to extend our debt maturities into 2014

As per technical analysis of this penny Stock ADX and Stockhastic given a buy signal and it Started up trend with RSI positive divergence and recently it breakout with very high volume
4) Recent company’s action also supporting our positive view, so Blockbuster Inc (BBI) you can consider for breakout penny Stock portfolio, and you can enter near $0.76 with $0.60 stop loss
5) This Stock trading with high volume so you can consider for penny Stock day trading also
6)

DM crossover and raising ADX with Stockhastic buy signal and breakout with high volume and sustain breakout point on following day is a ideal condition to buy Stock and in this penny Stock you found all this factors, still keep stop loss because penny Stock when turn negative we never know, so protect your investment stop loss is important
7)
BBI
QuestEx Receives Multi-Year Permit for Drilling on the Sofia Property and Commences Exploration Program
(Mon, 21 Jun 2021 11:30:00 +0000)
QuestEx Gold & Copper Ltd. (TSXV: QEX) ("QuestEx" or the "Company") is pleased to announce that the British Columbia ("BC") Ministry of Mines has issued a multi-year area-based permit that will allow QuestEx to begin a fully funded drill program at its 91 square kilometre ("km") 100% owned Sofia property in BC's prolific Toodoggone mining district.
Brickell Biotech Announces Publication of Japan Phase 3 Long-Term Safety and Efficacy Study Results for Sofpironium Bromide Gel, 5% (ECCLOCK®) in the Journal of Dermatology
(Tue, 01 Jun 2021 12:00:00 +0000)
BOULDER, Colo., June 01, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that the results from the Phase 3 long-term safety and efficacy study conducted in Japan by its development partner, Kaken Pharmaceutical Co., Ltd. (“Kaken”) were published in the peer-reviewed Journal of Dermatology1. The paper, entitled “A phase III, 52-week, open-label study to evaluate the safety and efficacy of 5% sofpironium bromide (BBI-4000) gel in Japanese patients with primary axillary hyperhidrosis,” is available online in English at the Wiley Online Library (click here). Kaken and Brickell first announced the release of the Japan pivotal Phase 3 study results in June 2020 and this is the first release of these long-term safety and efficacy results. Kaken received regulatory approval to manufacture and market ECCLOCK® in Japan for the treatment of primary axillary hyperhidrosis in September 2020 and launched commercial sales in November 2020. Japan is the first country to approve sofpironium bromide, which also marks the first approval of a topical prescription product for the treatment of primary axillary hyperhidrosis in Japan. “We are pleased to announce the publication of these data from Kaken’s Phase 3 long-term safety and efficacy study in the highly regarded peer-reviewed Journal of Dermatology. Publications such as this are a valuable clinical experience resource for Kaken during its commercialization of ECCLOCK® in Japan, as it further aids in acquainting Japanese physicians and healthcare professionals on prescribing sofpironium bromide, 5% as a potential best-in-class treatment for patients with primary axillary hyperhidrosis, a chronic medical condition,” said Deepak Chadha, Chief Research and Development Officer of Brickell. In addition, Brickell announced in its quarterly update on May 13, 2021 that it had completed enrollment in the U.S. Phase 3 Cardigan I study and exceeded 70% enrollment in the U.S. Phase 3 Cardigan II study. Both randomized, double-blinded, placebo-controlled pivotal studies are evaluating sofpironium bromide gel, 15% vs. placebo (1:1 ratio) in approximately 350 subjects (per study) aged nine and older with primary axillary hyperhidrosis. Brickell expects to report topline results from the Cardigan I and II pivotal studies in the fourth quarter of 2021. About Sofpironium Bromide Sofpironium bromide is Brickell’s lead investigational product candidate and is a new chemical entity that belongs to a class of medications called anticholinergics. Anticholinergics block the action of acetylcholine, a chemical that transmits signals within the nervous system that are responsible for a range of bodily functions, including activation of the sweat glands. Sofpironium bromide was retrometabolically designed. Retrometabolic drugs are intended to exert their action locally and are potentially rapidly metabolized into a less active metabolite once absorbed into the blood. Sofpironium bromide gel, 15% is currently being evaluated in a U.S. pivotal Phase 3 clinical program for the treatment of primary axillary hyperhidrosis, and sofpironium bromide gel, 5% is approved in Japan for the same indication under the brand name ECCLOCK®. Sofpironium bromide was discovered at Bodor Laboratories, Inc. by Dr. Nicholas Bodor D.Sc., d.h.c. (multi), HoF, Graduate Research Professor Emeritus, University of Florida. About Hyperhidrosis Hyperhidrosis is a debilitating, life-altering medical condition where a person sweats beyond what is physiologically required for thermoregulation of the body. More than 15 million people, or 4.8% of the population of the United States, and 12.76% of the population in Japan, are believed to suffer from hyperhidrosis2,3. Primary axillary (underarm) hyperhidrosis is the targeted first indication for sofpironium bromide and is the most common site of occurrence of hyperhidrosis, affecting an estimated 65% of patients with hyperhidrosis in the United States. Additional information can be found on the International Hyperhidrosis Society website: https://www.sweathelp.org/. About Brickell Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs. For more information, visit https://www.brickellbio.com. Cautionary Note Regarding Forward-Looking Statements Any statements made in this press release relating to future financial, business and/or research and clinical performance, conditions, plans, prospects, trends, or strategies and other such matters, including without limitation, the anticipated timing, scope, design and/or results of ongoing and future clinical trials, intellectual property rights, including the validity, term and enforceability of such, the expected timing and/or results of regulatory approvals and prospects for commercializing any of Brickell’s product candidates, or research collaborations with its partners, including in Japan, the United States or any other country, are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict,” “potential,” “look forward” and similar expressions and their variants, as they relate to Brickell, Kaken or any of Brickell’s partners, may identify forward-looking statements. Brickell cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time, often quickly and in unanticipated ways. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including without limitation, ability to obtain adequate financing to advance product development, ability to maintain and enforce intellectual property rights, potential delays for any reason in product development and clinical trial enrollment, regulatory changes, supply chain disruptions, unanticipated demands on cash resources, any disruption to its business caused by the current COVID-19 pandemic, interruptions, disruption or inability by Kaken to supply and commercialize the product in Japan, or obtain or retain adequate pricing or reimbursement, the outcome of Brickell’s ongoing U.S. Phase 3 pivotal program on sofpironium bromide gel, and other risks associated with developing and obtaining regulatory approval for and commercializing product candidates. Further information on the factors and risks that could cause actual results to differ from any forward-looking statements are contained in Brickell’s filings with the United States Securities and Exchange Commission (SEC), which are available at https://www.sec.gov (or at https://www.brickellbio.com). The forward-looking statements represent the estimates of Brickell as of the date hereof only, and Brickell specifically disclaims any duty or obligation to update forward-looking statements. 1 The Journal of Dermatology is the official peer-reviewed publication of the Japanese Dermatological Association and the Asian Dermatological Association.2 Doolittle et al. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res 2016; 308: 743-749.3 Fujimoto et al. Epidemiological study and considerations of focal hyperhidrosis in Japan. J Dermatol 2013; 40: 886-90. Brickell Investor Contact:Dan FerryLifeSci Advisors(617) 430-7576daniel@lifesciadvisors.com
Brickell Biotech Reports First Quarter 2021 Financial Results and Provides Corporate Update
(Thu, 13 May 2021 20:01:00 +0000)
Completed enrollment in Phase 3 pivotal Cardigan I study and exceeded 70% enrollment in Phase 3 pivotal Cardigan II study- - -Topline results for Phase 3 pivotal Cardigan I and Cardigan II studies expected in Q4 2021- - -Presented results from Phase 3 open-label, long-term safety study of sofpironium bromide gel, 5% & 15% at AAD VMX 2021 BOULDER, Colo., May 13, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced financial results for the first quarter ended March 31, 2021 and provided a corporate update. “The beginning of 2021 has been a very productive period for the Brickell team, as we continue to execute against our development strategy for sofpironium bromide gel, 15% as a potential best-in-class treatment option for primary axillary hyperhidrosis,” commented Robert Brown, Chief Executive Officer of Brickell. “Most importantly, we continue to see patient enrollment in our Phase 3 pivotal clinical studies meet expectations, with enrollment completed last month in the Cardigan I study, and 70% enrollment surpassed in the Cardigan II study. As a result, we are on track to announce topline data from both studies in the fourth quarter of 2021. If these studies are successful, we expect to proceed towards an NDA submission to the U.S. FDA in 2022.” Mr. Brown continued, “In April 2021, we were pleased to highlight data from the ARGYLE study, our Phase 3 open-label, long-term safety study of sofpironium bromide gel, as part of the late-breaking research program at the American Academy of Dermatology’s Virtual Meeting Experience 2021. In this study, sofpironium bromide gel was generally well-tolerated with continued efficacy during 48 weeks in patients with primary axillary hyperhidrosis. These data further contribute to our understanding of the long-term use of sofpironium bromide gel as a potential novel treatment for the millions of patients suffering from this chronic and debilitating condition.” Business and Recent Developments Completed enrollment in the Phase 3 Cardigan I study and exceeded 70% enrollment in the Phase 3 Cardigan II study. Both randomized, double-blinded, placebo-controlled pivotal studies are evaluating sofpironium bromide gel, 15% vs. placebo (1:1 ratio) in approximately 350 subjects (per study) aged nine and older with primary axillary hyperhidrosis.Presented results from the Phase 3 open-label, long-term safety study of sofpironium bromide gel, 5% and 15% in a late-breaking oral presentation at the American Academy of Dermatology’s Virtual Meeting Experience 2021 (“AAD VMX 2021”), in which the safety, tolerability, and efficacy results for sofpironium bromide gel, 5% and 15% were consistent with prior clinical experience and no unexpected safety findings were observed.Published validation results from the Company’s proprietary patient reported outcome scale, the Hyperhidrosis Disease Severity Measure-Axillary© (HDSM-Ax), in the peer-reviewed Journal of Drugs in Dermatology. The published results conclude that the HDSM-AX scale is a well-defined and reliable measure of primary axillary hyperhidrosis.Hosted a KOL event in March with leading dermatologists to discuss hyperhidrosis through both the eyes of a patient and diagnosing clinician, as well as the unmet need that exists in hyperhidrosis, the current treatment landscape, and the negative quality of life impacts experienced by both pediatric and adult patients.Japanese development partner, Kaken Pharmaceutical Co., Ltd. (“Kaken”), continued to ramp up commercialization efforts for sofpironium bromide gel, 5% (ECCLOCK®) in Japan.Strengthened the Company’s balance sheet to $34.8 million in cash and cash equivalents at the end of the first quarter of 2021, which includes aggregate net proceeds of $10.6 million from warrant exercises and the sale of shares under a previously filed At-The-Market Equity Offering Program during the first quarter of 2021. Upcoming Milestones On track to complete enrollment for the Cardigan II pivotal study in the third quarter of 2021.Expect to report topline results from the Cardigan I and II pivotal studies in the fourth quarter of 2021. Financial Results First Quarter 2021 Financial Results The Company reported cash and cash equivalents of $34.8 million as of March 31, 2021, compared to $30.1 million as of December 31, 2020. Revenue was approximately $17 thousand for the first quarter of 2021, compared to $1.0 million for the first quarter of 2020. Revenue in 2021 consisted of royalty revenue recognized related to sales of ECCLOCK® in Japan by Kaken, while revenue in 2020 was driven by collaboration revenue recognized for research and development activities related to a license agreement with Kaken pursuant to which Kaken provided research and development funding to Brickell. Research and development expenses were $6.1 million for the first quarter of 2021, compared to $2.7 million for the first quarter of 2020. This increase was primarily due to an increase in clinical costs related to the Phase 3 Cardigan studies, which were initiated in the fourth quarter of 2020. General and administrative expenses were $3.0 million for the first quarter of 2021, compared to $2.5 million for the first quarter of 2020. The increase was primarily due to increases in compensation-related expense and professional fees. Brickell’s net loss was $9.0 million for the first quarter of 2021 compared to $4.1 million for the first quarter of 2020. Conference Call and Webcast Information Brickell’s management will host a conference call today at 4:30 p.m. ET to discuss the financial results and recent corporate developments. The dial-in number for the conference call is 1-877-705-6003 for domestic participants and 1-201-493-6725 for international participants, with Conference ID #13718897. A live webcast of the conference call can be accessed through the “Investors” tab on the Brickell Biotech website at https://www.brickellbio.com. A replay will be available on this website shortly after conclusion of the event for 90 days. About Sofpironium Bromide Sofpironium bromide is Brickell’s lead investigational product candidate and is a new chemical entity that belongs to a class of medications called anticholinergics. Anticholinergics block the action of acetylcholine, a chemical that transmits signals within the nervous system that are responsible for a range of bodily functions, including activation of the sweat glands. Sofpironium bromide was retrometabolically designed. Retrometabolic drugs are intended to exert their action locally and are potentially rapidly metabolized into a less active metabolite once absorbed into the blood. Sofpironium bromide gel, 15% is currently being evaluated in a U.S. pivotal Phase 3 clinical program for the treatment of primary axillary hyperhidrosis, and sofpironium bromide gel, 5% is approved in Japan for the same indication under the brand name ECCLOCK®. Sofpironium bromide was discovered at Bodor Laboratories, Inc. by Dr. Nicholas Bodor D.Sc., d.h.c. (multi), HoF, Graduate Research Professor Emeritus, University of Florida. About Hyperhidrosis Hyperhidrosis is a debilitating, life-altering medical condition where a person sweats beyond what is physiologically required for thermoregulation of the body. More than 15 million people, or 4.8% of the population of the United States, and 12.76% of the population in Japan, are believed to suffer from hyperhidrosis1,2. Primary axillary (underarm) hyperhidrosis is the targeted first indication for sofpironium bromide and is the most common site of occurrence of hyperhidrosis, affecting an estimated 65% of patients with hyperhidrosis in the United States. Additional information can be found on the International Hyperhidrosis Society website: https://www.sweathelp.org/. About Brickell Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium bromide for the treatment of hyperhidrosis. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative and differentiated pharmaceutical products that Brickell believes can be successful in the marketplace and transform lives by solving currently unmet patient needs. For more information, visit https://www.brickellbio.com. Cautionary Note Regarding Forward-Looking Statements Any statements made in this press release relating to future financial, business and/or research and clinical performance, conditions, plans, prospects, trends, or strategies and other such matters, including without limitation, the anticipated timing, scope, design and/or results of ongoing and future clinical trials, intellectual property rights, including the validity, term and enforceability of such, the expected timing and/or results of regulatory approvals and prospects for commercializing any of Brickell’s product candidates, or research collaborations with its partners, including in Japan, the United States or any other country, are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict,” “potential,” “look forward” and similar expressions and their variants, as they relate to Brickell, Kaken or any of Brickell’s partners, may identify forward-looking statements. Brickell cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time, often quickly and in unanticipated ways. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including without limitation, ability to obtain adequate financing to advance product development, ability to maintain and enforce intellectual property rights, potential delays for any reason in product development and clinical trial enrollment, regulatory changes, supply chain disruptions, unanticipated demands on cash resources, any disruption to its business caused by the current COVID-19 pandemic, interruptions, disruption or inability by Kaken to supply and commercialize the product in Japan, or obtain or retain adequate pricing or reimbursement, the outcome of Brickell’s ongoing U.S. Phase 3 pivotal program on sofpironium bromide gel, and other risks associated with developing and obtaining regulatory approval for and commercializing product candidates. Further information on the factors and risks that could cause actual results to differ from any forward-looking statements are contained in Brickell’s filings with the United States Securities and Exchange Commission (SEC), which are available at https://www.sec.gov (or at https://www.brickellbio.com). The forward-looking statements represent the estimates of Brickell as of the date hereof only, and Brickell specifically disclaims any duty or obligation to update forward-looking statements. 1 Doolittle et al. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res 2016; 308: 743-749.2 Fujimoto et al. Epidemiological study and considerations of focal hyperhidrosis in Japan. J Dermatol 2013; 40: 886-90. Brickell Investor Contact:Dan FerryLifeSci Advisors(617) 430-7576daniel@lifesciadvisors.com Brickell Biotech, Inc.Condensed Consolidated Statements of Operations(in thousands, except share and per share data)(unaudited) Three Months EndedMarch 31, 2021 2020Revenue Collaboration revenue$— $1,046 Royalty revenue17 — Total revenue17 1,046 Operating expenses: Research and development6,052 2,664 General and administrative2,967 2,481 Total operating expenses9,019 5,145 Loss from operations(9,002) (4,099) Investment and other income (loss), net31 (4) Interest expense(34) — Net loss$(9,005) $(4,103) Net loss per common share attributable to common stockholders, basic and diluted$(0.15) $(0.45) Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted61,163,581 9,106,209 Brickell Biotech, Inc.Selected Financial InformationCondensed Consolidated Balance Sheet Data(amounts in thousands)(unaudited) March 31,2021 December 31, 2020Cash and cash equivalents$34,781 $30,115 Prepaid expenses and other current assets3,997 3,489 Total assets38,851 33,634 Total liabilities9,707 6,499 Total stockholders’ equity29,144 27,135
Brickell Biotech Inc to Host Earnings Call
(Thu, 13 May 2021 18:30:00 +0000)
NEW YORK, NY / ACCESSWIRE / May 13, 2021 / Brickell Biotech Inc (NASDAQ:BBI) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 13, 2021 at 4:30 PM Eastern Time.To listen to the event live or access a replay of the call - visit https://www.
Will Brickell (BBI) Report Negative Earnings Next Week? What You Should Know
(Thu, 06 May 2021 19:00:07 +0000)
Brickell (BBI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HCKT Hackett Group, Inc
SectorServices
RecommendationsBuy
Buy Near2.12
Stop Loss1.88
Posted Date6/6/2009 1:32:46 AM
First resistance3.04
Second resistance3.38
Third resistance5.44
First Support2.00
Second Support1.88
Comments
6/6/2009 3:45:25 PM0) Penny Stock Alert - Hackett Group, Inc
1) (HCKT) is a global strategic advisory firm and company is a leader in best practice advisory, benchmarking, and transformation consulting services, including shared services, outsourcing and off shoring advice
2) Hackett business application consulting services helps costumer to maximize returns on IT investments At the end of the first quarter of 2009, the Hackett Group, Inc
3) (HCKT) got cash balance $26.3 million, and as per company Stock repurchase plan, the Company already repurchased approximately 1.0 million shares at average price $2.08 per share, for a total cost of $2.1 million
4) And still approximately $4.8 million remained available under the Company’s share repurchase program.

Based on the current economic Outlook, the Hackett Group, Inc
5) (HCKT) estimates total revenue for the second quarter of 2009 to be in the range of $34.0 M to $36.0 M and estimates earnings per share to be in the range of $0.00 to $0.03. Recently Wipro Technologies (WIT) announced they partnered with Oracle for best-of-breed HR platform solutions and for that Wipro has also selected The Hackett Group (HCKT), to provide empirical data, best practices and world-class Performance insights on the development of its innovative bundled solution platform
6) The solution, allows employers to reduce and control cost as it provides an opportunity to centralize and standardize processes while eliminating duplicative management structures
7)

As per chart analysis Hackett Group, Inc
8) (HCKT) Relative Strength (RSI) started to strengthening, rate of change also got good moment again there are strong demand closer to $2.12 that indicating accumulation going on, with good capital in hand and suitable to present economy business model offering over all best penny Stock investing option
9)
HCKT
Do These 3 Checks Before Buying The Hackett Group, Inc. (NASDAQ:HCKT) For Its Upcoming Dividend
(Sat, 19 Jun 2021 08:30:54 +0000)
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see The Hackett...
Worldwide Calls for Social Reform and Racial Equality Drive Dramatic Plans to Expand Supplier Diversity Programs
(Thu, 17 Jun 2021 14:00:00 +0000)
MIAMI & LONDON, Jun 17, 2021--In response to the worldwide calls for social reform and racial equality, companies are making plans to dramatically expand their Supplier Diversity programs over the next few years, according to a new study from The Hackett Group, Inc. (NASDAQ: HCKT).
Here's Why Momentum in Hackett Group (HCKT) Should Keep going
(Tue, 15 Jun 2021 12:50:12 +0000)
Hackett Group (HCKT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Why Hackett Group (HCKT) Stock Might be a Great Pick
(Mon, 14 Jun 2021 12:54:12 +0000)
Hackett Group (HCKT) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Will Hackett Group (HCKT) Gain on Rising Earnings Estimates?
(Mon, 07 Jun 2021 16:20:04 +0000)
Hackett Group (HCKT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
LOJN LO-JACK CORP COM
SectorSecurity Systems & Services
RecommendationsBuy
Buy Near3.84
Stop Loss3.21
Posted Date2/8/2009 12:00:00 AM
First resistance5.33
Second resistance6.73
Third resistance7.20
First Support3.41
Second Support3.21
Comments
2/8/2009 12:42:24 PM0) LoJack Corporation (LOJN), the company that invented the stolen vehicle recovery market more than two decades ago, is the global leader in finding and recovering a wide range of mobile assets including cars, construction equipment and motorcycles having recovered more than $5 billion USD in stolen assets worldwide
1) In today's rapidly changing world, LoJacks core competencies are more valuable and more relevant than ever as they are now being applied into new areas, such as the prevention, detection and recovery of stolen cargo and finding and rescuing people with cognitive disorders such as Alzheimers and autism
2) LoJack has the proven processes, ultimate technology for recovery ,Radio Frequency and unique integration with law enforcement agencies, making its offerings the most effective solutions that not only deliver a wide range of recoveries, but also enhance the safety of the public on a global level
3) LoJacks Stolen Vehicle Recovery System operates in 26 states and the District of Columbia, and in more than 30 countries throughout North America, South America, Europe, Africa and Asia
4) This Penny Stock looks good candidate for portfolio investment
5) Before to invest Penny Stock understand your risk
6) To manage your risk keep tight stop loss on all investment.
LOJN
ANAD ANADIGICS Inc
SectorSemiconductors
RecommendationsBuy
Buy Near2.16
Stop Loss1.90
Posted Date2/8/2009 12:00:00 AM
First resistance2.55
Second resistance3.06
Third resistance3.92
First Support2.16
Second Support1.90
Comments
2/8/2009 12:45:38 PM0) ANADIGICS, Inc
1) is a provider of semiconductor solutions in the broadband wireless and wire line communications markets
2) The Company’s products include power amplifiers (PAs), tuner integrated circuits, active splitters, line amplifiers and other components, which can be sold individually or packaged as integrated radio frequency (RF) and front end modules This penny Stock closer to its strong support and looks good candidate for portfolio investment
3) Before to invest in penny Stock understand the risk factor
4) Due to market and economic condition keep tight stop loss on all investment.
ANAD
CHUX O CHARLEYS INC COM
SectorRestaurants
RecommendationsBuy
Buy Near2.66
Stop Loss1.96
Posted Date2/8/2009 12:00:00 AM
First resistance3.14
Second resistance5.44
Third resistance7.30
First Support2.05
Second Support1.23
Comments
2/8/2009 12:50:26 PM0) OCharleys Inc
1) is a casual dining restaurant company
2) The Company owns and operates three restaurant concepts under the OCharleys, Ninety Nine and Stony River Legendary Steaks trade names
3) As of December 30, 2007, it operated 229 OCharleys company owned restaurants in 16 states in the Southeast and Midwest, 115 Ninety Nine restaurants in nine Northeastern states, and ten Stony River restaurants in six states in the Southeast and Midwest OCharleys beats by $0.13, misses on revs Reports Q4 (Dec) loss of $0.15 per share, $0.13 better than the First Call consensus of ($0.28); revenues fell 5.7% year/year to $202.9 mln vs the $206.8 mln consensus The main difference here is that OCharleys would have still closed out its latest quarter in the red without writing down the value of its assets
4) This penny Stock closer to its strong support and looks good candidate for portfolio investment
5) Before to invest in any penny Stock understand your risk
6)
CHUX
ACTG Acacia Research Corporation
SectorTechnology : Electronic Instr. & Controls
RecommendationsBuy
Buy Near3.01
Stop Loss2.42
Posted Date1/1/2009 12:00:00 AM
First resistance3.61
Second resistance4.60
Third resistance5.55
First Support3.01
Second Support2.84
Comments
1/1/2009 8:55:19 PM0) Acacia Research Corporation (ACTG) has given a breakout with high volume and also given a buy signal, with rising moving average
1) Stockhastic, rate of change (ROC) and ADX also given a buy signal Acacia Research Corporation (ACTG) announced on Dec 31 2008 that its subsidiary, Data Network Storage LLC, Telematics Corporation, International Printer Corporation and Light Valve Solutions LLC has entered into a settlement and license agreement with the Hewlett-Packard Company relates to storage area networks, Datatrac Corporation, Océ, N.V
2) and Océ North America, Inc
3) and Hitachi, Ltd respectively
4) Recently Acacia Research Corporation (ACTG) bought the rights to a patent related to wireless data technology and its subsidiary, Acacia Patent Acquisition LLC, has acquired the rights to patents relating to vehicle occupant sensing technology.

As per technical analysis and fundamental research Acacia Research Corporation (ACTG) looks good candidate for penny Stock investing as well as you can add in portfolio investment
5) Recently ACTG given a breakout with rising moving average and also Stockhastic and Rate of change (ROC) given a buy signal
6) Acacia Research Corporation (ACTG) you can consider for Investment, Swing Trading, penny Stock Investing, Day trading
7) Due to market and economic condition keep tight stop loss on all position
8) You can buy Acacia Research Corporation (ACTG) near $3.01
ACTG
Here's Why Acacia Research (NASDAQ:ACTG) Can Manage Its Debt Despite Losing Money
(Wed, 19 May 2021 05:33:46 +0000)
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Acacia Research Corp. to Host Earnings Call
(Mon, 17 May 2021 13:15:00 +0000)
NEW YORK, NY / ACCESSWIRE / May 17, 2021 / Acacia Research Corp. (NASDAQ:ACTG) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 17, 2021 at 11:00 AM Eastern Time.
Acacia Research Reports First Quarter 2021 Financial Results
(Mon, 17 May 2021 12:17:00 +0000)
Acacia Research Corporation (NASDAQ: ACTG) today reported results for the three-month period ended March 31, 2021.
Acacia Research to Release First Quarter 2021 Financial Results
(Mon, 10 May 2021 10:00:00 +0000)
Acacia Research Corporation ("Acacia" or "the Company") (NASDAQ: ACTG) announced today it will release its first quarter 2021 financial results on Monday, May 17, 2021 at 8:00 a.m. ET/ 5:00 a.m. PT.
Shareholder broadside at biotech investor Arix’s board
(Sat, 10 Apr 2021 18:10:52 +0000)
Arix Bioscience, the biotechnology investor backed by restaurant tycoon Richard Caring and biotech entrepreneur Sir Christopher Evans, has been forced to halt two board appointments after its largest shareholder called for a total overhaul in a scathing letter. Mayfair-based Arix has had to pause the planned hire of two directors due to join the business this month after Acacia Research, an American investor advised by Neil Woodford, said in a damning public letter that the firm faced “seemingly uncontrollable board tumult” and was being led by a “woefully inadequate investment group” after 18 director departures in five years. In response, Arix said it had an experienced board and was already building its investment team in the UK and the US. Fallen fund manager Mr Woodford is not advising Acacia on this saga, people familiar with the matter said. Arix was due to welcome Dr Axel Wieandt, a former Morgan Stanley and Deutsche Bank banker, on to the board alongside biotech expert James Noble. However it has told investors that while the pair remain “highly qualified” the appointments are on hold while it reviews parts of the business including “the question of board composition”.
LAB LABRANCHE & CO INC COM
SectorFinancial
RecommendationsBuy
Buy Near6.23
Stop Loss4.72
Posted Date11/2/2008 12:00:00 AM
First resistance7.43
Second resistance7.98
Third resistance11.80
First Support5.70
Second Support4.72
Comments
11/3/2008 12:00:04 AM0) LaBranche & Co Inc.com (LAB)Stocks given a double top breakout on 10/31/08 with good volume again many technical indicators also have given a buy signal, with rising moving average
1) Stockhastic and ADX also given a buy signal
2) LaBranche & Co Inc.com (LAB) is a Stock-exchange specialist firm
3) As per technical analysis and fundamentally LaBranche & Co Inc.com (LAB) look good candidate for portfolio investment. LaBranche & Co Inc.com you can consider for Investment, Swing trading, Stock trading, penny Stock Investing, Day trading
4) Due to market and economic condition keep tight stop loss on all position
5) You can buy LaBranche & Co Inc.com (LAB) near $6.23
LAB


Next Page >>   

 

























Home for ۩ Day Trading | Breakout Stock trading system | Penny Stock Investing | Market Research

Contact Us | Affiliate | Disclaimer | Feedback | Help | Site Map | RSS  RSS
All Rights Reserved © 2000-2006 Flyingstock.com
Penny Stock picks for Stock trading Penny Stock investing support resistance

This Service is solely an information service provided by the automated software tool & is for entertainment purposes only. It should be understood that there is no guarantee that past performance of our stock trading system or day trading Strategy or Penny stock picks will be indicative of future results.